Milestone Pharmaceuticals (MIST) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Milestone Pharmaceuticals has announced the appointment of two new independent directors, Stuart Duty and Andrew Saik, to its Board of Directors, with a third to be appointed soon. This move comes as the company, known for developing innovative cardiovascular medicines, enters an exciting period. Additionally, current directors Debra K. Liebert and Richard C. Pasternak will not seek reelection at the upcoming Annual Meeting.
For further insights into MIST stock, check out TipRanks’ Stock Analysis page.